Current Strategies for the Immunotherapy of Multiple Myeloma. Oncology (Williston Park) 2017 Jan 15;31(1):55-63
Date
01/17/2017Pubmed ID
28090624Scopus ID
2-s2.0-85050440905 (requires institutional sign-in at Scopus site)Abstract
The introduction of cellular immunotherapies using genetically modified T cells has revolutionized the treatment of patients with B-cell lymphomas. However, despite the progress made in this field, similarly effective immunotherapeutic approaches have not yet been identified for patients with solid tumors or other hematologic malignancies such as multiple myeloma. Here we outline the most promising novel cellular immune strategies for patients with multiple myeloma. In addition, we highlight combinatorial approaches that, it is hoped, will further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, possibly, even cures.
Author List
Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic DAuthor
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansImmunotherapy
Lymphocytes, Tumor-Infiltrating
Multiple Myeloma
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
